Uroplasty to Issue First Quarter of Fiscal 2013 Financial Results on July 26, 2012
MINNEAPOLIS, July 12, 2012 /PRNewswire/ — Uroplasty, Inc. (NASDAQ: UPI) announced today that it will release financial results for the first quarter of fiscal 2013 ended June 30, 2012, at the market close on Thursday, July 26, 2012. The Company will host a conference call to discuss these results on Thursday, July 26, 2012 at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). David Kaysen, President and Chief Executive Officer, and Medi Jiwani, Vice President, Chief Financial Officer and Treasurer, will host the call. Individuals wishing to participate in the conference call should dial 877-941-8631. An audio replay will be available for 30 days following the call at 800-406-7325 (domestic) and 303-590-3030 (international), with the passcode 4550883#.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared neuromodulation system that delivers posterior tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.
For Further Information: Uroplasty, Inc. EVC Group David Kaysen, President and CEO, or Doug Sherk (Investors), 415.652.9100 Medi Jiwani, Vice President, CFO, Jenifer Kirtland (Investors), Treasurer 415.568.9349 952.426.6140 Chris Gale (Media), 646.201.5431 ------------ --------------------------------
SOURCE Uroplasty, Inc.